New Double Epigenetic Regimen in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia

Inclusion Criteria: * Adults aged ≥ 18 and ≤ 70 years * Patients diagnosed with AML according to 2016 WHO myeloid malignant disease diagnosis standard (Non-APL) * Patients with AML must meet one of the following criteria, A or B: A: Refractory AML disease was defined as follows: (1) failure to attain CR following exposure to at least 2 courses of standard or intensive induction therapy; or (2) bone marrow leukemia cell decline index (BMCDI) \< 50% and \> 20% after 1 course of standard or intensive induction therapy. B: Relapsed AML disease was defined as follows: (1) reappearance of leukemic blasts in the peripheral blood after CR; or (2) detection of ≥ 5% blasts in the BM not attributable to another cause (e.g., BM regeneration after consolidation therapy); or (3) extramedullary relapse. * ECOG performance status score less than 3 * Expected survival time ˃ 3 months * Patients without serious heart, lung, liver, or kidney disease * Ability to understand and voluntarily provide informed consent Exclusion Criteria: * Patients who are allergic to the study drug or drugs with similar chemical structures * Pregnant or lactating women, and women of childbearing age who do not want to practice effective methods of contraception * Active infection * Active bleeding * Patients with new thrombosis, embolism, cerebral hemorrhage, or other diseases or a medical history within one year before enrollment * Patients with mental disorders or other conditions whereby informed consent ca…